1154 results
Thumbnail

D3.143 - Seasonal Patterns of Airborne Pollen in Ecuador: Influence of Wet and Dry Seasons on Allergenic Taxa Concentrations

Thumbnail

D3.144 - Geographic Disparities in Air Pollution and Th2-Mediated Airway Inflammation in Mexico City: The Role of Industrial and Traffic Emissions

Thumbnail

D3.146 - Impact of Switching from Omalizumab to Dupilumab in Severe Asthma Patients: A Retrospective Evaluation of Efficacy and Inflammatory Biomarkers

Thumbnail

D3.17 - Systemic Histaminergic Findings in Children with Chronic Urticaria

Thumbnail

D3.170 - Effectiveness and Safety Study of Subcutaneous Immunotherapy for Respiratory Allergy to Dermatophagoides and Lepidoglyphus Destructor

Thumbnail

D3.178 - Efficacy of Index of reactivity (IR) liquid sublingual immunotherapy in allergic rhinoconjunctivitis: A systematic review and meta-analysis of randomised studies

Thumbnail

D3.179 - Safety of 300IR liquid sublingual immunotherapy of cat allergen extract for respiratory allergy to cat dander: a post-marketing experience

Thumbnail

D3.18 - Allergy to Isobornyl Acrylate (IBOA) present in Sensors and Insulin Infusion Systems in Pediatric Population

Thumbnail

D3.180 - Good patient adherence to sublingual immunotherapy for allergic rhinitis can be achieved, when ENT-physicians collaborate with pharmacies in a straightforward adherence programme

Thumbnail

D3.182 - Health Economic Evaluation of 5-Grass Pollen Sublingual ImmunotherapyTablets for Grass Pollen-Induced Allergic Rhinitis in Finland, Norway and Sweden

Thumbnail

D3.183 - Reduction in Healthcare Resource Utilization in patients treated with 300 IR liquid SLIT: Real-World Evidence from Spain and Italy

Thumbnail

D3.184 - Treatment with the 300 IR house dust mite sublingual tablet is safe and well tolerated in adults and adolescents in a real-world data setting – results of a non-interventional post authorization safety study

Thumbnail

D3.185 - The 300 IR house dust mite sublingual tablet is effective and well tolerated in patients with allergic rhinoconjunctivitis and concomitant allergic asthma in a real-world data setting

Thumbnail

D3.186 - A new allergenic protein in holm oak (Quercus ilex) pollen: Glutathione-S-transferase

Thumbnail

D3.187 - Adverse reactions to sublingual immunotherapy with carbamylated allergoids of different sources in clinical studies

Thumbnail

D3.188 - Comparison of Completion Rates and Factors Influencing Discontinuation in Paediatric Allergen Immunotherapy: A Five-Year Single-Center Experience

Thumbnail

D3.189 - Adverse reactions to subcutaneous immunotherapy for mite in children and adolescents in a tertiary care center

Thumbnail

D3.19 - Evaluation of allergens in Atopic Dermatitis in children between 6 months and 18years

Thumbnail

D3.190 - Follow up cases of subcutaneous allergen Immunotherapy in respiratory allergic diseases continuing for 10-30years “A Real life experience of 14 cases”

Thumbnail

D3.191 - Case report: Acute systemic reactions to sublingual immunotherapy for tree pollen